by Eclosion Team | Apr 18, 2017 | Uncategorized
Geneva (Switzerland), April 18, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today the initiation of a Phase 2a clinical study in Australia...